Elevated levels of NORAD expression are detected in a series of human epithelial breast cancer cell lines (MDA-MB-231, MDA-MB-436, and MDA-MB-468), which are classified as the most aggressive subtypes known as triple-negative breast cancer. Here, NORAD is linked to breast carcinoma.